FDA Staff Flags Concerns on Capricor's Deramiocel Ahead of AdCom
CAPR sits 84% above its 52-week low of $4.3 on elevated volume (1.9× avg).
Summary
FDA staff reviewers raised concerns about whether deramiocel has sufficient evidence of effectiveness for treating Duchenne cardiomyopathy, per briefing documents released today. This directly threatens the drug's approval prospects just two days before the July 29 advisory committee meeting. The negative staff review follows the June 26 PDUFA date announcement and the ongoing lawsuit against distributor NS Pharma, which already clouds commercialization. With a $1.1B market cap largely tied to deramiocel's approval, this regulatory setback could materially impact the stock. The advisory committee's discussion and vote on July 29 will be the next critical catalyst.
At the time of this announcement, CAPR was trading at $7.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $4.30 to $40.37. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Reuters.